Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms

6 Mar 2019

Abstract excerpt

The 2016 World Health Organization classification introduced a number of genes with somatic mutations and a category for germline predisposition syndromes in myeloid neoplasms. We have designed a comprehensive next-generation sequencing assay to detect somatic mutations, translocations, and germline mutations in a single assay and have evaluated its clinical utility in patients with myeloid neoplasms. Extensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30840646
DOI: 10.1371/journal.pone.0212228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasmsPMID 30840646Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.Semantic proximity Read ↗

Applications of next-generation sequencing in hematologic malignancies.Semantic proximity Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasmsSemantic proximity Read ↗

The role of next-generation sequencing in hematologic malignanciesSemantic proximity Read ↗

Identifying potential germline variants from sequencing hematopoietic malignancies.Semantic proximity Read ↗

Identifying potential germline variants from sequencing hematopoietic malignancies.Semantic proximity Read ↗

Molecular findings in myeloid neoplasms.Semantic proximity Read ↗

Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

Molecular diagnostics of acute myeloid leukemia: it's a (next) generational thing.Semantic proximity Read ↗

Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.Semantic proximity Read ↗

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.Semantic proximity Read ↗

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.